Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by Sheba Medical Center.
Recruitment status was  Recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: June 19, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted
To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.

Condition Intervention
Retinopathy of Prematurity
Drug: erythropoietin and early iron supplements

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: The Possible Influence of Erythropoietin and Early Iron Supplements on the Prevalence and Severity of Retinopathy of Prematurity and Other Short Term Outcome of Prematurity

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Estimated Enrollment: 400
Study Start Date: April 2006
Estimated Study Completion Date: December 2006

Ages Eligible for Study:   up to 3 Months   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all premature infants with birth weight of 1250 grams or less

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00339001

Contact: Jacob Kuint, MD 972-3-5303030 ext 2227
Contact: Irit Eisen, MD 972-3-5303030 ext 2227

Neonatal Department, Sheba Medical Center Recruiting
Ramat-Gan, Israel, 52621
Contact: Jacob Kuint, MD    972-3-5303030 ext 2227   
Contact: Irit Eisen, MD    972-3-5303030 ext 2227      
Principal Investigator: Irit Eisen, MD         
Sub-Investigator: Robi Chaviv, med. student         
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Jacob Kuint, MD Sheba Medical Center
  More Information Identifier: NCT00339001     History of Changes
Other Study ID Numbers: SHEBA-06-4128-JK-CTIL 
Study First Received: June 19, 2006
Last Updated: June 19, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:
Retinopathy of prematurity

Additional relevant MeSH terms:
Retinopathy of Prematurity
Infant, Premature, Diseases
Premature Birth
Retinal Diseases
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Eye Diseases
Infant, Newborn, Diseases
Epoetin Alfa
Trace Elements
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on October 21, 2016